AIF1 and Alzheimer disease: The Iba1 staining (Fig. 3 and SI Fig. 5), allowed the blinded raters to separate the TLR9 p.E317D mutation carriers and other AD cases (i.e., PSEN1 mutation carriers and sporadic AD patients) from the neurologically healthy control individuals.